Evidence map›Paper›PMID 42086706›Full record

ArticleNPJ precision oncology2026

Predicting immunotherapy benefit in leiomyosarcoma through active chromatin cfDNA profiling.

Carlos Diego Holanda Lopes, Hsin-Ta Wu, Katharine Dilger, Yue Wendy Zhang, Abdulazeez Salawu, Lee-Anne Stayner, Abha A Gupta, Aaron R Hansen, Anna Spreafico, Philippe L Bedard and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Carlos Diego Holanda LopesPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Hsin-Ta WuAqtual, Hayward, CA, USA.
Katharine DilgerAqtual, Hayward, CA, USA.
Yue Wendy ZhangAqtual, Hayward, CA, USA.
Abdulazeez SalawuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Lee-Anne StaynerPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Abha A GuptaPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Aaron R HansenPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Anna SpreaficoPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Philippe L BedardPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Maggie C LouieAqtual, Hayward, CA, USA.
Lillian L SiuPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
Albiruni R Abdul RazakPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada. albiruni.razak@uhn.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leiomyosarcoma (LMS) is an aggressive soft-tissue sarcoma characterized by epigenomic dysregulation and variable responsiveness to checkpoint inhibitors (CPIs). In this study, we evaluated a novel liquid biopsy platform based on circulating cell-free DNA active chromatin (cfDNA

Identifiers

PMID42086706
PMCPMC13350727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.